药明康德官网介绍，药明康德为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。服务范围 涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研究等领域。目前，公司的赋能平台正承载着来自全球30多个国家约6,000家合作伙伴的研发 创新项目。 | FH FRAT | # 企业探索信息 经营网站网站 PHOPERS | | | --- | --- | --- | | | 谓输入企业名称、统一社会信用代码或注册号 | | | 无锡药明康德新药开发股份有限公司 存续(在常、开业、在册) | | 发送报告 | | 统一社会信用代码:91320200724183068U | | | | 注册号： | | 信息分享 | | 法定代表人: GE LI(李英) | | | | 登记机关: 无锡市市场监督管理局 | | 信息打印 | | 成立日期: 2000年12月01日 | | | | 基础信息 | 行政许可信息 行政处罚信息 列入经营屏带名录信息 列入严重违法失信名单（黑名单）信息 公告信息 | | | ■营业执照信息 | | | | · 统一社会信用代码: 9132020 ...

Core Insights - WuXi AppTec (603259) reported a revenue of RMB 9.655 billion for Q1 2025, representing a year-on-year growth of 20.96% [1] - The net profit attributable to shareholders reached RMB 3.672 billion, showing a significant increase of 89.06% year-on-year [1] - The company’s backlog of orders for ongoing operations stood at RMB 52.33 billion, reflecting a growth of 47.1% compared to the previous year [1] Revenue Breakdown - The chemical business generated revenue of RMB 7.39 billion, marking a year-on-year increase of 32.9% [2] - The small molecule drug discovery segment contributed to the revenue by successfully synthesizing and delivering over 460,000 new compounds in the past 12 months, a growth of 6% [2] - The small molecule development and manufacturing (D&M) segment achieved revenue of RMB 3.85 billion, up 13.8% year-on-year [2] TIDES Business Performance - The TIDES business (oligonucleotides and peptides) saw revenue reach RMB 2.24 billion, a remarkable growth of 187.6% [3] - The backlog for TIDES orders increased by 105.5% year-on-year, with a 14% rise in the number of clients served [3] - The company is expanding its peptide production capacity, expecting to exceed 100,000L by the end of 2025 [3] Testing and CRO Services - The testing business generated revenue of RMB 1.29 billion, with a focus on new molecular services across various fields [3] - The clinical CRO and SMO services reported revenue of RMB 410 million, with SMO revenue growing by 5.5% [3] - The CRO services assisted clients in obtaining 10 clinical trial approvals, while SMO empowered 28 products to gain market approval [3] Biological Business and Future Outlook - The biological business achieved revenue of RMB 610 million, reflecting an 8.2% year-on-year growth [4] - The company’s CEO emphasized the return to double-digit growth in both revenue and profit, with a strong order backlog [4] - WuXi AppTec maintains its guidance for 2025, expecting a revenue growth of 10%-15% for ongoing operations [4]